Acquisition and Presentation of Tumor Antigens by Dendritic Cells
- PMID: 26853848
- DOI: 10.1615/critrevimmunol.v35.i5.10
Acquisition and Presentation of Tumor Antigens by Dendritic Cells
Abstract
Dendritic cells (DCs) are master regulators of the immune response and, because of their peculiar features in antigen acquisition, processing, and presentation, they play a critical role in activating an efficient antigenspecific T-lymphocyte response against tumors. However, the DC family is composed of different cell subsets, which may differently contribute to tumor-specific T-cell activation. In addition to the DC subset involved, the induction of a tumor-specific adaptive immune response is also dependent on DC interactions with other innate cell effectors, such as natural killer cells. The different modalities by which DCs can acquire tumor antigens also significantly affect antigen presentation because, in addition to the presentation of tumor antigens on MHC class II upon the classical exogenous antigen processing pathway, DCs are equipped to directly activate cytotoxic T cells via both cross-priming and cross-dressing. Here, the different forms of tumor antigen presentation by DCs are reviewed and discussed. We also discuss the ways in which this novel information could be exploited in the design of DC-based cancer vaccines.
Similar articles
-
Dendritic Cells and Cancer Immunity.Trends Immunol. 2016 Dec;37(12):855-865. doi: 10.1016/j.it.2016.09.006. Epub 2016 Oct 25. Trends Immunol. 2016. PMID: 27793569 Free PMC article. Review.
-
Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.Oncotarget. 2016 Jul 5;7(27):41053-41066. doi: 10.18632/oncotarget.9419. Oncotarget. 2016. PMID: 27203391 Free PMC article.
-
Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.Int J Cancer. 2015 Mar 1;136(5):1085-94. doi: 10.1002/ijc.29087. Epub 2014 Aug 6. Int J Cancer. 2015. PMID: 25046660
-
Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.Cytotherapy. 2016 Apr;18(4):570-80. doi: 10.1016/j.jcyt.2016.01.005. Cytotherapy. 2016. PMID: 26971685
-
Engineering anti-cancer nanovaccine based on antigen cross-presentation.Biosci Rep. 2019 Oct 30;39(10):BSR20193220. doi: 10.1042/BSR20193220. Biosci Rep. 2019. PMID: 31652460 Free PMC article. Review.
Cited by
-
Immune responses against autologous tumor and human papilloma virus in lymph nodes from patients with penile cancer.Investig Clin Urol. 2021 Jan;62(1):39-46. doi: 10.4111/icu.20200116. Epub 2020 Dec 10. Investig Clin Urol. 2021. PMID: 33314806 Free PMC article.
-
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.Cancers (Basel). 2021 Jan 4;13(1):134. doi: 10.3390/cancers13010134. Cancers (Basel). 2021. PMID: 33406696 Free PMC article. Review.
-
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.Hum Vaccin Immunother. 2023 Dec 31;19(1):2198467. doi: 10.1080/21645515.2023.2198467. Epub 2023 May 3. Hum Vaccin Immunother. 2023. PMID: 37133853 Free PMC article.
-
Dendritic cell vaccines for melanoma: past, present and future.Melanoma Manag. 2016 Dec;3(4):273-289. doi: 10.2217/mmt-2016-0014. Epub 2016 Nov 29. Melanoma Manag. 2016. PMID: 30190899 Free PMC article. Review.
-
Immunometabolic reprogramming, another cancer hallmark.Front Immunol. 2023 May 19;14:1125874. doi: 10.3389/fimmu.2023.1125874. eCollection 2023. Front Immunol. 2023. PMID: 37275901 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials